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ABSTRACT
Objective: To estimate the cost-effectiveness of
adalimumab plus methotrexate (MTX) versus MTX
monotherapy in early, aggressive rheumatoid arthritis
(RA) when explicitly modelling short-term (reversible)
and long-term (irreversible, ie, joint damage) disease
activity and physical function.
Methods: A microsimulation model was developed to
unify, in a single cost-effectiveness model, measures of
reversible and irreversible disease activity and physical
function based on data from the PREMIER trial. Short
term, reversible disease activity was modelled using
DAS28 variables, including swollen joint counts, tender
joint counts, C reactive protein concentration and pain.
The DAS28 variables were then used in a logistic
regression to predict short-term American College of
Rheumatology (ACR) responses, which informed
treatment continuation and switches. Long term,
irreversible, radiographically documented joint damage
was modelled using modified Total Sharp Score (mTSS).
The model then linked both short-term disease activity
and mTSS to the Health Assessment Questionnaire
score, which was used to calculate direct and indirect
costs, and quality adjusted life-years (QALYs).
Results:When both reversible and irreversible effects of
therapy were included, combination therapy was
estimated to produce 6-month 50% ACR responses in
75% of patients versus 54% in MTX monotherapy.
Compared to MTX monotherapy, combination therapy
resulted in 2.68 and 3.04 discounted life years and
QALYs gained, respectively. Combination therapy also
resulted in a net increase in direct costs of £106 207 for
a resulting incremental cost/QALY gain of £32 425. When
indirect costs were included in the analysis, the ICER
(incremental cost-effectiveness ratio) decreased to
£27 238. Disregarding irreversible effects increased the
incremental cost-effectiveness ratio to £78 809 (when
only direct costs were included).
Conclusions: Starting with adalimumab plus MTX
combination therapy in early, aggressive RA is cost-
effective when irreversible damage is adequately
considered.
Strengths and limitations of this study
▪ Many published models consider only short-term
outcomes and thus do not fully capture the ben-
efits of successful treatment in terms of prevent-
ing or slowing radiographic progression of
rheumatoid arthritis (RA). The present approach
better reflects the potential impact of therapy on
patients through explicit and separate modeling
of the short- and long-term effects of adalimu-
mab combined with methotrexate (MTX) versus
MTX monotherapy in patients with early RA.
▪ Clinical pathways applied in RA management in
the UK were included in the present model.
Specifically, after initial therapy with disease-
modifying antirheumatic drugs, UK patients are
usually offered biologics. Their disease is moni-
tored, and non-responders are switched to the
next therapy in their treatment sequence.
▪ The results of the present analysis only reflect
the population (ie, early, aggressive RA) and
comparators (ie, first-line therapy with adalimu-
mab+MTX or MTX monotherapy) included in the
PREMIER trial, on which this analysis is based,
and therefore cannot be readily extrapolated to
other populations and other therapies.
▪ The effectiveness of therapies given after first
line represent patients with more established RA.
It is possible that treatment efficacy would be
higher in the modelled cohort because patients
with early RA would be expected to have a
greater probability of treatment response.
▪ Although the model considered UK clinical path-
ways, some specific aspects were not accounted
for, including (1) the assumption that response
would be assessed earlier in the care pathway
due to the early, aggressive nature of the type of
RA studied and (2) the use of ACR criteria to
measure response instead of DAS28, which is
more often used in the UK.
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INTRODUCTION
Rheumatoid arthritis (RA) is a progressive, inﬂammatory
disease that affects synovial tissue, resulting in joint swel-
ling, stiffness, pain and tenderness.1 The short-term
course of RA is characterised by alternating periods of
ﬂares—in which reversible, clinical signs of inﬂammation
and pronounced symptoms are present—and periods of
symptom-free remission.2 3 Inﬂammation of the affected
joint(s) throughout the course of the disease may lead to
erosion of articular cartilage and marginal bone, result-
ing in irreversible joint destruction.3 Radiographic
studies have shown that joint damage typically occurs as
early as 6 months after onset of RA and may progress
rapidly during the ﬁrst 2 years.4 5 Consequently, the
optimal therapeutic window to prevent or inhibit this
damage, and the associated health impairments and costs
may be early in the disease course.
In contrast to symptomatic anti-inﬂammatory and anal-
gesic treatment options for RA, methotrexate (MTX)
and other non-biological disease-modifying antirheu-
matic drugs (DMARDs) are efﬁcacious in reducing the
reversible symptoms of RA and preventing or slowing its
irreversible course, and are currently recommended as
ﬁrst-line therapy.6–9 Several biological DMARDs, such as
tumour-necrosis factor (TNF) antagonists adalimumab,
etanercept, inﬂiximab and golimumab have demon-
strated effective disease modiﬁcation and symptom
control with acceptable beneﬁt-risk proﬁles in patients
with early moderate-to-severe RA.10–13
Clinical trials have demonstrated better clinical
response rates and radiographic outcomes with MTX in
combination with anti-TNF agents compared with either
monotherapy.14–22 A disadvantage of anti-TNF agents
compared with non-biological DMARDs is that these are
relatively expensive and, as such, tend to be relegated for
use after DMARD failure. However, in some RA popula-
tions—such as those with an early and/or aggressive form
of RA—the beneﬁts of earlier treatment with anti-TNF
agents may outweigh their costs. From a cost-effectiveness
perspective, differing conclusions regarding the health
economic value of initial anti-TNF therapy have been
reported, with some studies reporting favourable cost-
effectiveness results,23–25 although others have been less
favourable.26–29 However, ﬁrm conclusions about the cost-
effectiveness of RA treatments may be difﬁcult to draw
because of important differences across studies, includ-
ing selection of analytical perspectives and assumptions
concerning long-term efﬁcacy, safety of treatment, stop-
ping rules and source of efﬁcacy data. For instance, in
previous cost-effectiveness analyses of anti-TNF agents
for early RA, the stopping rules (ie, whether response
and continuation of therapy are based on explicit cri-
teria) have varied widely, from American College of
Rheumatology (ACR) response criteria to Disease Activity
Scores to literature-based evidence; and no two papers
used the same source of evidence to estimate the efﬁcacy
of comparator treatments.23–25 27–29 In particular, in
previous economic analyses, the long-term impact of RA
(in terms of radiographically documented joint damage),
if included at all, was generally modelled implicitly via
measured changes in the functional outcomes (ie,
Health Assessment Questionnaire (HAQ)—a generic
functional questionnaire assessing patient’s ability to
carry out everyday activities that may be affected by both
reversible and irreversible components of RA)23 24 or
indirectly via the impact of radiological damage on
HAQ.25 26 Modelling joint damage captures the cumula-
tive effects of treatment over time, yet the irreversible
radiographic damage itself has never been explicitly and
directly modelled. This represents an important potential
gap because the impact of long-term irreversible disease
progression on health-related quality of life (HRQL) and
costs is an arguably critical driver of cost-effectiveness and
to a large degree, one of the main reasons, if not the
main reason, for why early, aggressive RA should be
treated as effectively as possible.
The model presented herein was, therefore, designed
to ﬁll this important gap and explore how—when expli-
citly and separately modelled—the short term, symptom-
atic effects and long term, radiographic progression of
RA affect costs and quality of life in measurable and dif-
ferent ways. This conceptual framework was applied to
assess the cost-effectiveness of adalimumab plus MTX
combination therapy in early, aggressive RA. By unifying
these attributes into a single modelling framework, the
hope is that ultimately such a model may be used to
make predictions about the outcomes of clinical trials
for these therapies.
METHODS
Model overview
The incremental cost-effectiveness ratio (ICER) of adali-
mumab+MTX versus MTX monotherapy was assessed by
modelling, via microsimulation, the associated direct
(and, in a scenario, indirect costs) and quality-adjusted
life-years (QALYs) over 30 years from a UK (UK)
National Health Service (NHS) perspective.
The PREMIER study is the principal evidence source
used to derive model parameter values. Detailed results of
this pivotal randomised clinical trial conducted over
2 years in MTX-naïve patients with early aggressive RA,
comparing adalimumab as monotherapy (n=274) or com-
bined with MTX (n=268) versus MTX monotherapy
(n=257), have been described elsewhere.15 Additionally,
economic data were derived from the health economic
companion study to PREMIER, Study DE032.30 The
characteristics of patients in the companion study (N=664)
were similar to those included in the full PREMIER trial
(N=799) in terms of age, gender, disease duration, prior
DMARD use, disease activity, HAQ score and discontinu-
ation.15 30 Response rates were slightly higher in DE032
(72% in adalimumab+MTX vs 50% in MTX in DE032 vs
62% in adalimumab+MTX vs 46% in MTX in the full
PREMIER data). Since the relationships between mod-
elled variables (eg, the effect of disease activity and Total
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Sharp Score on HAQ, and the estimation of resource use
as a function of HAQ) are independent of treatment
effect, data from all Study DE032 patients were used in the
quantiﬁcation of these relationships.
Model structure, relationships and key inputs
The microsimulation model generates individual patient
histories. These histories tell the story of each individual
patient’s disease pathway in terms of his/her therapy
and its consequences on disease activity and joint
damage, and the subsequent consequence of these on
survival, costs and quality of life. While side effects
and mortality may occur any moment, treatment deci-
sions are made in 26-week cycles, for 1000 patients
initiated on adalimumab plus MTX therapy or MTX
monotherapy (ﬁgure 1).
The histories are generated using analyses which have
been carried out on the information available in the
PREMIER clinical trial.15
Each patient history starts when they enter the model
(ﬁgure 1) with a given score on the “28-joint Disease
Activity Score” (DAS28): which reﬂects the number of
tender joints (0–28), number of swollen joints (0–28),
a pain score (0–100 mm visual analogue scale), and a
value for the C reactive protein (CRP) concentration. This
is a short-term reﬂection of disease activity. Additionally,
each patient is given a score on the modiﬁed Total Sharp
Score (mTSS), which assesses radiological damage among
44 joints and which reﬂects long-term irreversible damage.
For each patient, the starting scores on the four
DAS-28 domains are computer generated by drawing at
random from a multivariate normal distribution which
was estimated using the sample means and covariance of
the logit of the four domains. The effect of therapy was
modelled by shifts in the distribution means, reﬂecting
improvements. These shifts are again generated using a
multivariate normal distribution as estimated by the
sample means and covariance as observed in PREMIER.
Naturally, while the shifts in the means capture the
improvements in the scores, the covariance matrix cap-
tures the positive correlation between the four domains.
As a consequence of the fact that this correlation is not
perfect, one will ﬁnd that patients improve on one, but
not necessarily on another, domain of the DAS score.
The initial score for the mTSS is generated by drawing
from the sample distribution at the start of the model.
Figure 1 Model schematic.
ACR, American College of
Rheumatology; DAS, Disease
Activity Score; HAQ, Health
Assessment Questionnaire.
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This variable assesses radiological damage among 44
joints and captures joint destruction or deformity
which may result from irreversible joint erosion and
joint space narrowing, the long-term effects of RA. The
effect of treatment on mTSS was modelled as a linear
function of treatment (tx) and time (months). The
effect for subsequent treatment strategies are assumed
to be the same as those applied for MTX (please refer
to supplementary material for additional information).
The DAS28 variables are then used in an ordered logis-
tic regression to predict ACR responses at 26 weeks. After
26 weeks, patients who failed to meet the 50% improve-
ment criteria of the ACR50 switched to the next treat-
ment in the sequence of three other treatment strategies,
which was identical for both treatment arms: ﬁrst MTX
+hydrochloroquine, then leﬂunomide monotherapy and
then gold monotherapy. This sequence of treatments was
chosen because it includes therapies that target RA in dif-
ferent ways. Each treatment is thus considered a suitable
alternative for patients who failed on the previous treat-
ment in the sequence. The order of the treatments in the
sequence was chosen such that the cost of treatments
increases with each failed option. Further, the sequence
of treatments that we apply has been used previously in
economic modelling of biologics in RA.24
Patients reaching ACR50 on a given therapy remained
on that therapy until discontinuation due to adverse
events (AEs). If an ACR50 response was not reached in a
given cycle, patients discontinued their current treatment
and switched to the next therapy in the sequence.
Patients failing to reach ACR50 on any of the four treat-
ment strategies were assumed to switch back to, and
remain on, the therapy that provided best response
(which was estimated in the same way as when prescribed
the ﬁrst time) until discontinuation due to AEs.
AE-related discontinuations were estimated to have
occurred in 2% of patients annually regardless of therapy
on the basis of the PREMIER randomised clinical trial.15
Assumptions about the efﬁcacy of secondary DMARDs
after insufﬁcient response to either primary treatment
were obtained from a Swedish study of patients with estab-
lished RA.31 Details of model estimates are provided in
the online supplementary appendix.
Disease activity and mTSS were linked to an indivi-
dual’s HAQ using an equation that was based on an ana-
lysis of PREMIER and adjusted for the observation that
the relationship between mTSS and HAQ was more pro-
nounced in patients when in remission (please refer to
supplementary material for additional information) (3).
The probability of death at any point in time was
related to the patient’s age and HAQ score using the
relationship reported by Sokka et al,32 for the data from
PREMIER were not suitable to estimate survival rates.
Economic data (from the PREMIER health economic
subset), which included employment status (employed,
unemployed, self-employed, homemaker, student,
retired, other), work-related information (average
working time, work days missed and self-reported visual
analogue scale measuring the degree to which RA
affected normal work or homemaking performance),
and healthcare resource use (number of hospital visits
and duration of hospital stays and number of visits to a
general practitioner (GP)), were mathematically linked
to a patient’s HAQ score at any point in time. Again,
these links are described elsewhere.33
Further details on the relationships described above
can be found in the online supplementary appendix.
Quality of life inputs
Utilities, derived from the Health Utilities Index Mark
3 (HUI3), were estimated based on data from
PREMIER. A logistic curve was applied, with utility as the
dependent variable and HAQ score as the explanatory
variable (see online supplementary appendix).
Cost inputs
Treatment costs were based on estimates from the
September 2013 British National Formulary.34 The cost of
adalimumab therapy was based on 40 mg treatment every
other week by self-injection, whereas the cost of MTX
assumed a treatment strategy of 7.5 mg weekly, adminis-
tered orally. The annual costs of MTX and adalimumab
therapies were estimated to be £22.92 and £11 269.18,
respectively, taking into account the PREMIER-based pro-
portion of patients who received dose escalations. The
annual costs of other DMARD therapies were estimated to
be £31.33, £248.14 and £700.96 for hydrochloroquine,
leﬂunomide and gold, respectively. Unit costs for hospital
and GP visits were taken from the Personal Social Services
Research Unit Costs of Health and Social Care, and are
inﬂated to 2012 prices using the Hospital and Community
Health Services Index.30 35 36 A hospital visit cost £290.00
per hospital bed day, and a GP visit cost £29.83. The cost
of a day missed from work was estimated to be £89.60,37
considering the UK average weekly wage.
Analyses
The primary outcome was the discounted ICER, which
was assessed in the base case analysis and various scen-
ario and probabilistic sensitivity analyses. Unless other-
wise speciﬁed, the costs and QALY outcomes were
discounted at 3.5%, as per current National Institute for
Health and Care Excellence (NICE) research
guidelines.38
The following alternative scenarios were considered:
(1) the effects of the mTSS on HAQ (ie, the irreversible
effects of untreated RA) were ignored; (2) mortality
effects were ignored; (3) treatment response was deﬁned
as 70% (ie, ACR70); (4) the impact of an additional
HAQ point on utility was assumed to be halved to test the
impact of choosing an HRQL measure other than the
HUI3 to model utility; (5) the model analytical horizon
was shortened to 2, 5 and 10 years (alternating between
including and ignoring the irreversible damage); and (6)
discontinuation rates of 0% and 4% were tested.
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A probabilistic sensitivity analysis (PSA) combined
bootstrapping with random draws from uncertainty distri-
butions. By bootstrapping the data from the randomised
clinical trial using normal and Poisson distributions, we
obtained uncertainty margins surrounding the annual
increase in mTSS; the distribution of initial response; the
relationship between clinical response variables and
HAQ; and the relationship between HAQ and utility, loss
of work, days in hospital, doctor visits and mortality.
All remaining estimates were from sources other than
PREMIER. For these estimates, uncertainty distributions
were deﬁned as follows and were used to draw from each
bootstrap. The base case annual incidence of AEs was
multiplied with a factor that followed a Programme
Evaluation and Review Technique (PERT) distribution, a
version of the β distribution, with mean=1, minimum=0.5,
and maximum=1.5. A similar approach was chosen for the
parameter modelling the dependency between HAQ and
mTSS and those for the efﬁcacy and AEs of later therapies.
Less uncertainty was assumed concerning the unit costs of
days missed from work and costs of hospital stays and GP
visits (PERT distributions for multiplication with mean=1,
minimum=0.8 and maximum=1.2). The PSA generated
250 simulations each with 1000 patients per treatment
arm. Results are presented via a cost-effectiveness accept-
ability curve.
This research was conducted by Pharmerit
International with the ﬁnancial support of AbbVie Inc.
AbbVie Inc. participated in the design and conduct of
the study and in the interpretation of the data.
RESULTS
Primary model
The clinical outcomes at 2 years mimic the data observed
in PREMIER despite the fact that, in contrast to the trial,
the model assumed that patients would begin to switch
medications after 6 months and could try up to three
other agents before reverting to the treatment on which
they experienced the best response. Unless otherwise spe-
ciﬁed, all results exclude indirect costs.
Figure 2 presents the distribution over time of the
1000 patients on the various treatment sequences for
each arm of the model. As depicted on ﬁgure 2, there is
a precipitous drop of patients on initial MTX monother-
apy after 26 weeks because 46% of these patients did not
achieve ACR50. This drop is less pronounced for com-
bination therapy because 75% of patients achieved
ACR50. These estimates are slightly higher than the
response rates seen in the patient-level data. This may
be explained by the use of data from all Study DE032
patients to inform the estimates of intervariable relation-
ships. Thereafter, patients switched from their initial
therapy only because of AEs. Response rates for the next
treatment lines were estimated to be much lower, and a
sizeable percentage of patients ended up in the last
option of best previous treatment (17% MTX patients,
5% combination patients). The average mTSS increases
almost linearly from a base line value of 18 to an
average value of 106 with combination therapy and an
average value of 157 with MTX.
The differences in clinical response presented in
ﬁgure 2 result in differences in HAQ scores and asso-
ciated modelled consequences in terms of resource util-
isation (GP visits, hospital days), survival and utilities,
which are illustrated in ﬁgure 3. Patients started with a
relatively high average HAQ score of approximately 1.5,
which decreased to an average of approximately 0.7 for
patients who started on combination therapy (black line,
top left panel, ﬁgure 3) and to approximately 0.9 for
patients who started on MTX monotherapy (grey line,
top left panel, ﬁgure 3). These curves reﬂect a weighted
average of responders and non-responders. MTX mono-
therapy was also associated with lesser HRQL (average
difference of 0.21 on the utility scale between the two
treatment arms) and greater resource use in terms of
both GP visits and hospitalisations. Table 1 presents an
overview of the estimated differences in clinical and
costs outcomes after 30 years.
Discounted life expectancy was estimated to be 12.62
versus 9.94 for combination therapy versus MTX mono-
therapy, respectively, an incremental gain of 2.68 life
years in the combination treatment arm. Discounted
Figure 2 Distribution of patients on each treatment
sequence over time by initial therapy. The bottom stratum
represents the number of patients on initial therapy (MTX
monotherapy or adalimumab+MTX, labelled ⓪), and the
stratum above it represents the number of patients on the first
of three treatment sequences (MTX+hydrochloroquine,
labelled ①), and so on (leflunomide, labelled ②; gold,
labelled ③). Patients who have failed the initial therapy and all
3 subsequent lines switched to the therapy with the best
response. Patients in this group are presented in the fourth
stratum (labelled ④). The top portion represents those who
have died (labelled ⑤).
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QALYs were 6.83 versus 3.79, respectively, a gain of 3.04
QALYs in the combination treatment arm. Patients who
started on combination therapy were estimated to remain
on their initial therapy for an average of 13.32 years com-
pared with 6.62 years for patients who started on MTX
monotherapy. The associated discounted cost of medica-
tion were estimated to be £108 805 and £2 589, respect-
ively, corresponding to a net cost of £106 217 favouring
MTX. However, the more effective combination therapy
was also associated with savings in terms of hospitalisa-
tions and GP visits, such that the total net cost for com-
bination therapy was estimated to be £98 558.
Accordingly, the ICER excluding indirect costs was esti-
mated to be £32 425. When indirect costs were included
in the analysis, the ICER decreased to £27 238.
Alternative scenarios
Table 1 also shows the balance between costs and effects
when four key alternate scenarios are modelled.
Speciﬁcally, excluding the effects of irreversible damage
on HAQ led to more modest increases in patient life-
span and incremental QALYs, which had a dramatic
effect on the cost-effectiveness ratio; it increased to
>£70 000. When survival beneﬁts were ignored, the
ICER improved to approximately £23 000. This improve-
ment was driven primarily by increased costs associated
with more patients surviving in the MTX arm, which
resulted in decreased incremental costs. When therapy
was stopped and replaced with the next treatment in the
sequence in patients who did not achieve an ACR70
response, fewer patients received biologics in the com-
bination therapy arm and less time was spent on this
therapy. However, this change did not have a marked
effect on the ICER: the costs decreased but the savings
and the beneﬁts also decreased, with the ICER changing
from £32 425 to £30 198/QALY. Assuming an attenuated
relationship between HAQ and utility (as may be
expected if a utility measure other than the HUI3 is
used to model patient-related quality of life) increased
the ICER to £38 611/QALY owing to fewer incremental
QALYs observed.
Using analytic horizons of 2, 5 and 10 years resulted in
ICERs of £95 947, £56 014 and £37 948, respectively.
When shorter time horizons were assumed, the full
beneﬁt of treatment in terms of preventing or slowing
the progression of RA was not realised. This is demon-
strated by the modest differences in QALYs seen
between the treatments in the shorter term. Further,
when the effects of mTSS on HAQ were also excluded,
the ICERs for the 2, 5 and 10 years horizon analyses
increased to £190 481, £126 756, and £90 249, respect-
ively. The relative contribution to the ICER of the irre-
versible damage component is thus 49.6%, 55.8% and
58% at 2, 5 and 10 years, respectively. When the discon-
tinuation rate was set to 0% and 4%, the ICERs were
£32 494 and £32 315, respectively.
Probabilistic sensitivity analyses
Figure 4 presents the cost-effectiveness acceptability
curve. The probability that combination therapy is cost-
effective was estimated to be 100% at willingness-to-pay
thresholds of £45 000 and above when the base case
model assumptions were applied (ﬁgure 4). The esti-
mates, conditional on the model used in the base case
here, were extremely robust.
DISCUSSION
Decision-making for chronic disease therapies should
consider both short-term and long-term effects.
Figure 3 Consequence of
treatments. Grey lines represent
patients who started on
methotrexate (MTX)
monotherapy. Black lines
represent patients who started on
combination therapy (adalimumab
+MTX). HAQ, Health Assessment
Questionnaire; GP, general
practitioner; QALY,
quality-adjusted life-years.
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Accordingly, models for RA treatments that look only at
short-term outcomes (ie, 2–10 years)25 27 28 do not fully
capture the beneﬁts that successful treatment may bring
in terms of preventing or slowing the radiographic pro-
gression of RA, which may lead to improved physical
function, reduced direct medical costs and increased
productivity and HRQL. Likewise, measures of short-
term reversible disease activity and therapeutic response
are only part of the story because the potential to
prevent or slow irreversible damage may be far more
important. Thus, models of biologics that have focused
on short-term disease activity, measured as DAS2828 or
with HAQ23 24 as the single explicitly modelled variable,
offer a limited perspective.
The present model was designed speciﬁcally to
provide a unifying view in which parameter inputs for
both short-term and long-term outcomes were modelled
explicitly and separately in patients with a speciﬁc early,
aggressive form of RA. The different components of the
reversible short-term disease activity were captured using
a multivariate normal model with shifted means of the
DAS28 variables to accurately reproduce the results of
the PREMIER trial. The irreversible joint damage of RA
was modelled using the mTSS—which assesses radio-
graphic damage in 44 different joints—independently
from the short-term disease activity and HAQ, to reﬂect
the results of adalimumab+MTX and MTX monotherapy
as observed in PREMIER. Ultimately, this unifying mod-
elling approach is designed to allow simulation and pre-
diction of clinical trial results.
The analyses presented herein indicate that relative to
MTX monotherapy, combination with adalimumab
+MTX offers an acceptable ICER and a reasonable treat-
ment choice for patients with early, aggressive RA. The
treatment choice for combination adalimumab+MTX
therapy relative to MTX monotherapy resulted in gains
of 3.04 discounted QALYs and net discounted direct
costs of £98 558 over 30 years. Hence, the ICER was esti-
mated to be £32 425. These results were shown to be
consistent in univariate deterministic and multivariate
probabilistic sensitivity analyses. Importantly, separate
scenario analyses demonstrated that when the analytical
horizon was reduced to 2 years, the ICER increased to
£95 947. When the irreversible effects of RA were
ignored, the ICER increased to over £70 000/QALY
gained. When considering alternative time horizons and
at the same time omitting the impact of irreversible
effects, we found that the irreversible effects of RA have
the greatest impact on cost-effectiveness in the longer-
term (49.6% in the 2-year analysis vs 58.9% over
30 years) and that the reversible effects are larger drivers
of the short-term outcomes.
Finally, when indirect costs were included (ie, a UK
societal perspective was taken), the ICER decreased to
£27 238/QALY gained.
Similar to this study, Davies et al24 concluded that early
anti-TNF therapy in combination with MTX was cost-
effective relative to MTX alone. Like the current model,
this study adopted a patient simulation approach that
allowed patients to switch treatments if they did not
respond. As patients progressed through the sequences
of treatment, the modelled HAQ score deteriorated over
time, with periods of response resulting in slower disease
progression. HAQ scores were then linked to costs and
utilities via regression equations. Cost-effectiveness was
further improved by including productivity costs and
mimicking the impact of irreversible radiographic pro-
gression. Kobelt25 showed early treatment with etaner-
cept plus MTX to be cost-effective versus MTX
monotherapy.
Here, irreversible joint damage was assumed to affect
HAQ. However, both approaches were not so explicit as
in the current model.
Based on the current analysis and evidence from
previously published models, it is apparent that the
assumptions made concerning longer term effects
meaningfully affect the conclusions of an economic
modelling study in RA. The choice of the perspective,
stopping rules, and the target patient population will
affect cost-effectiveness results. Schipper et al28 did not
demonstrate positive cost-effectiveness results with bio-
logical therapy in patients with early RA. This model,
however, did not include radiographic damage and
adopted a short-term (5-year) perspective. The stopping
rule applied in the model was based on DAS28 variables
(patients not in remission at 3 months, ie, DAS-28 >2.6,
switched to the next treatment in the sequence).
Progression was also based solely on changes in DAS28,
rather than incorporation of a combination of DAS28
and HAQ scores, which occurs in the majority of pub-
lished models, including the present one. Finckh et al26
in a very early patient with RA population (symptoms
onset <3 months) concluded that the cost-effectiveness
with biologics remains uncertain. This conclusion
mainly stemmed from concerns surrounding the data
applied in the economic model. The two most notable
concerns were (1) that many of the statistical relation-
ships were estimated based on a cohort of patients with
established RA, and (2) that extrapolating efﬁcacy data
from such a patient population could underestimate the
beneﬁt of more aggressive early treatment.
Several limitations should be considered when gener-
alising conclusions from our model. Speciﬁcally, it was
based on patients in PREMIER, who were classiﬁed as
having early, aggressive RA. Hence, the results of the
present analysis cannot be extrapolated to other patient
populations. Second, the comparator arm included in
this model for ﬁrst-line therapy (ie, MTX monotherapy)
reﬂects the comparator arm of the PREMIER trial. In
practice, a combination of DMARD therapy is usually
given to patients with RA. However, because of the lack
of data, it was not possible to include a comparison with
a combined DMARD therapy arm. As a result, the efﬁ-
cacy and costs and AE rates of the comparator arm may
be underestimated in this model. Third, the effective-
ness of therapies given after ﬁrst line were taken from
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sources reporting on patients with more established RA.
It is possible that the efﬁcacy of these treatments would
be higher in the modelled cohort because patients with
early RA would be expected to have a greater probability
of treatment response.39 This factor is not expected to
affect the cost-effectiveness results presented herein sub-
stantially because, from second-line onwards, the same
sequence of treatment strategies was administered in
both treatment arms. Additionally, cost savings due to
work loss are not easily generalisable because these are
often heterogeneous across patients, and many analyses
exclude these costs for this reason. In addition, the
model here may underestimate the indirect cost savings
when considering a young working individual and may
overestimate these savings when considering an older,
non-working individual. Finally, patients with chronic RA
have been shown to have better utility than is seen in
the current model after 15–20 years (ﬁgure 3). This dif-
ference is explained by the PREMIER patients’ much
worse baseline HAQ scores (and hence modelled utility)
than is expected for patients with early RA.
Important general RA management principles in the
UK were included in the present model. Speciﬁcally,
after initial therapy with DMARDs, UK patients are
usually offered biologics. Their disease is monitored,
and non-responders are switched to the next therapy in
their treatment sequence. In the current model, data
are based on patients with early, aggressive RA.
Therefore, treatment with biologics is assessed earlier in
the care pathway than is current practice in the UK. As
indicated by the results, there may be a beneﬁt in treat-
ing patients earlier in this way, especially in terms of
avoiding irreversible joint damage. However, it is
acknowledged that in UK clinical practice, RA is usually
monitored through measurement of CRP and key com-
ponents of disease activity by using a composite score
such as DAS28, with an improvement of 1.2 DAS points
considered as an adequate response to treatment.40 In
the current model, ACR criteria are instead used to
measure response. ACR criteria are determined through
a combination of DAS28 components and pain score.
The discrepancy in responder status between DAS28
and ACR response criteria has previously been shown to
be less than 5%41 and as such, we do not expect the use
of different criteria to change the conclusions from our
model. Furthermore, in scenario analyses we showed
that altering the response hurdle does not greatly affect
conclusions of cost-effectiveness.
In conclusion, the results of this new modelling
approach, which sought to integrate explicitly into a
single unifying framework the reversible and irreversible
effects of RA, suggest that starting with combination
therapy in early, aggressive RA is not only effective, but
is also associated with an acceptable balance between
costs and effects. The results also indicate that when the
impact of irreversible radiographic damage is ignored,
the cost-effectiveness ratio of treatments for early RA
may be overestimated.
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